Abstract
In recent Coimbra' Conference, on the pre-launch of pathogen reduced-FFP for the local clinical use, the question was raised, by the moderator, on the efficacy of the current methodology used for prion removal processes and its influence on the overall quality and safety of the final product. This brief paper put together by speaker of this session and the moderator, as a consensus of opinions, which was largely discussed during Q&A session, to make it available to a large group of readers of transfusion apheresis science, who might be interested to this topic. In short the capacity of the current process of Octaplas to remove prion is in order of 5.6 log10/ID50 reduction based on several animal studies. Moreover the changes in coagulation and inhibitors are within acceptable range and bioequivalent to untreated FFP with no sign of inferiority. This paper describes in brief a technology update on solvent/detergent treated plasma, an alternative to FFP but with increased pathogen safety. The biochemical profile of the final product is comparable with FFP and contains all clinically relevant plasma proteins. Furthermore, Octaplas is a product that, in long term, reduces health care costs.
References
Oct 28, 1998·Vox Sanguinis·L Biesert, H Suhartono
Apr 15, 2000·Vox Sanguinis·P R FosterA C Bailey
Mar 15, 2006·Transfusion·Pranee KrailadsiriMarc Turner
Aug 29, 2006·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·B G Solheim, J Seghatchian
Jan 31, 2008·Haemophilia : the Official Journal of the World Federation of Hemophilia·P Brown
Jul 16, 2008·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Tor-Einar SvaeJürgen Römisch
Apr 28, 2009·Vox Sanguinis·A HegerJ Römisch
Jun 25, 2009·Vox Sanguinis·A Neisser-SvaeT-E Svae
Jan 15, 2010·Haemophilia : the Official Journal of the World Federation of Hemophilia·A PedenJ W Ironside
May 8, 2010·The Ceylon Medical Journal·B W P HabaragamuwaC A G S Piyasiri
Sep 16, 2010·Vox Sanguinis·A S LawrieS J Machin
Nov 19, 2010·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Margreet C van EerdMaria A de Peuter
Nov 11, 2011·Vox Sanguinis·A HegerT-E Svae
Jan 17, 2013·Transfusion·Petra Jilma-StohlawetzBernd Jilma
May 28, 2013·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Eline L HuismanMaria A de Peuter
Jan 1, 2014·Emerging Infectious Diseases·Jean Yves DouetOlivier Andreoletti
Jan 30, 2014·Transfusion·José CoeneVeerle Compernolle
Feb 14, 2014·Journal of Blood Medicine·Piers Blombery, Marie Scully
Aug 26, 2014·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Eline L HuismanMaria A de Peuter
Oct 12, 2014·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Gail Rock
Citations
Mar 10, 2015·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Jerard Seghatchian
Jun 5, 2018·Anesthesia and Analgesia·Jakob StensballePär I Johansson
Jun 19, 2017·Annals of Hematology·Giovanni Di MinnoAndreas Tiede